Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid

Journal of Clinical Microbiology

Volumn 49, Issue 5, 2011, Pages 2027-2030

  Van Burgel, N D ^a   Bakels, F ^a   Kroes, A C M ^a   Van Dam, A P ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL13 CHEMOKINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; CHILD; CONTROLLED STUDY; CRYPTOCOCCOSIS; DIFFERENTIAL DIAGNOSIS; ENCEPHALITIS; ERYTHEMA CHRONICUM MIGRANS; FACIAL NERVE PARALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYME DISEASE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RADICULITIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREPONEMATOSIS; VIRUS MENINGITIS;

ADULT; CEREBROSPINAL FLUID; CHEMOKINE CXCL13; CHILD; CHILD, PRESCHOOL; CLINICAL LABORATORY TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; HUMANS; LYME NEUROBORRELIOSIS; SENSITIVITY AND SPECIFICITY;

EID: 79955540344     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00084-11     Document Type: Article

References (13)

1. Blanc, F., et al. 2007. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology 69:953-958. (Pubitemid 47366047)
2. Cagigi, A., et al. 2008. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood 112:4401-4410.
3. Ljøstad, U., and A. Mygland. 2008. CSF B-lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J. Neurol. 255:732-737.
4. Mygland, A., et al. 2010. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur. J. Neurol. 17:8-16.
5. Rupprecht, T. A., U. Koedel, B. Angele, V. Fingerle, and H. W. Pfister. 2006. Cytokine CXCL13 - a possible early CSF marker for neuroborreliosis. Nervenarzt 77:470-473. (In German.)
6. Rupprecht, T. A., et al. 2005. The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65:448-450. (Pubitemid 41099810)
7. Schiffer, L., et al. 15 November 2010, posting date. Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus doi:10.1177/0961203310383301.
8. Schiffer, L., et al. 2009. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol. Dial. Transplant. 24:3708-3712.
9. Segal, B. M., and E. L. Logigian. 2005. Sublime diagnosis of Lyme neuroborreliosis. Neurology 65:351-352.
10. Sellebjerg, F., et al. 2009. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73:2003-2010.
11. Senel, M., et al. 2010. The chemokine CXCL13 in acute neuroborreliosis. J. Neurol. Neurosurg. Psychiatry 81:929-933.
12. Tjernberg, I., A. J. Henningsson, I. Eliasson, P. Forsberg, and J. Ernerudh. 2011. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. J. Infect. 62:149-158.
13. Widney, D. P., et al. 2005. Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J. Interferon Cytokine Res. 25:702-706. (Pubitemid 43010525)